Update on the Use of Steroids in Rheumatoid Arthritis
| Autor: | Blanca García-Magallón, Lucía Silva-Fernández, Jose Luis Andreu-Sanchez |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
musculoskeletal diseases
Drug medicine.medical_specialty business.industry media_common.quotation_subject General Medicine Disease medicine.disease Surgery Arthritis Rheumatoid Clinical trial Safety profile Adrenal Cortex Hormones Internal medicine Rheumatoid arthritis Humans Medicine Corticosteroid use business Clinical scenario media_common |
| Zdroj: | Reumatología Clínica (English Edition). 9:297-302 |
| ISSN: | 2173-5743 |
| DOI: | 10.1016/j.reumae.2013.01.015 |
| Popis: | Corticosteroids are a mainstay in the therapy of rheumatoid arthritis (RA). In recent years, a number of high-quality controlled clinical trials have shown their effect as a disease-modifying anti-rheumatic drug (DMARD) and a favorable safety profile in recent-onset RA. Despite this, they are more frequently used as bridge therapy while other DMARDs initiate their action than as true disease-modifying agents. Low-dose corticosteroid use during the first two years of disease slows radiologic damage and reduces the need of biologic therapy aimed at reaching a state of clinical remission in recent-onset RA. Thus, their systematic use in this clinical scenario should be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect